

Information for Colorado Prescribers of Prescription Drugs

ATTRUBY™ (acoramidis) tablets

The Colorado Wholesale Acquisition Cost Disclosure Law (Colorado House Bill 19-1131) requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing.

The “WAC Price” listed below represents the Company’s reported catalog or list price for the product sold to wholesalers, as reported by the manufacturer to applicable pricing compendia at or around the date indicated. WAC does not reflect discounts, rebates and other reductions in price. The price paid by patients may differ from the WAC listed below and may be determined by the individual patient’s insurance coverage.

| NDC | Product Name | Pack Size | WAC/Pack Price |
|---------------|--------------------------|-----------|----------------|
| 82228-0712-28 | ATTRUBY™ (acoramidis) | 112 | \$18,759.12 |

Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” The following generic prescription drugs are in the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) as the listed product:

None

©2024 BridgeBio Pharma, Inc. All rights reserved. MAT-US—445 V2

Source: FirstDataBank 11-26-2024